Cepheid sees FY13 non-GAAP EPS 41c-46c, consensus 12c Sees FY13 revenue $375M-$385M, consensus $396.52M. Sees FY13net income to range from a net loss of (5c)-1c. Expected non-GAAP net income excludes approximately $29M related to stock compensation expense and approximately $4M related to the amortization of acquired intangibles. The fully diluted share count for the year is expected to be approximately 72M, except in the event of a GAAP loss where the share count would be approximately 67M shares.
Cepheid upgraded to Buy from Hold at Craig-Hallum Craig-Hallum upgraded Cepheid to Buy and raised its price target to $75 from $52. The firm said Cepheid is rapidly expanding its clinical offering and customer reach and is emerging as the leading platform for molecular diagnostics.